Lazari Capital Management Inc. Decreases Position in Johnson & Johnson (NYSE:JNJ)

Lazari Capital Management Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 26.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 5,667 shares of the company’s stock after selling 1,988 shares during the quarter. Lazari Capital Management Inc.’s holdings in Johnson & Johnson were worth $883,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Hibernia Wealth Partners LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at $27,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson during the third quarter valued at $37,000. Tower View Wealth Management LLC boosted its position in Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC boosted its position in Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after purchasing an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC acquired a new stake in Johnson & Johnson during the second quarter valued at $48,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $156.76 on Friday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The stock has a market capitalization of $377.37 billion, a PE ratio of 11.35, a P/E/G ratio of 2.63 and a beta of 0.53. The stock has a 50-day simple moving average of $158.20 and a 200 day simple moving average of $158.83.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The business had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the previous year, the firm earned $2.35 EPS. The firm’s revenue was down 9.7% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is 34.47%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, February 6th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, January 24th. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $180.00 in a research report on Friday, December 1st. Finally, Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Check Out Our Latest Analysis on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.